

David Leon Copolov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8490273/publications.pdf>

Version: 2024-02-01

73
papers

3,184
citations

186265

28
h-index

149698

56
g-index

77
all docs

77
docs citations

77
times ranked

3511
citing authors

#	ARTICLE	IF	CITATIONS
1	Antipsychotic treatment in clinical high risk for psychosis: Iatrogenesis related to dopamine supersensitivity psychosis?. Australian and New Zealand Journal of Psychiatry, 2022, 56, 97-97.	2.3	0
2	Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs. Molecular Psychiatry, 2022, 27, 88-94.	7.9	15
3	Real-world performance of Victorian hospitals during the COVID-19 lockdowns. Australasian Psychiatry, 2022, 30, 239-242.	0.7	3
4	Responses to the opinion-based algorithms driving the National Mental Health Service Planning Framework. Australian and New Zealand Journal of Psychiatry, 2021, 55, 1208-1209.	2.3	0
5	The Butterfly Effect: Poor access to non-acute psychiatric beds and the emergency department congestion crisis in WA. Australian and New Zealand Journal of Psychiatry, 2021, , 000486742110256.	2.3	0
6	Re-balancing Victorian psychiatric services: Will increasing the supply of community services impact upon hospital demand?. Australian and New Zealand Journal of Psychiatry, 2021, , 000486742110257.	2.3	1
7	Response to Myles et al.: Changing the policy narrative on psychiatric inpatient care. Australian and New Zealand Journal of Psychiatry, 2021, , 000486742110484.	2.3	0
8	Pareto's law of the vital few: Patient requirements for hospital based non-acute care. Australian and New Zealand Journal of Psychiatry, 2020, 54, 205-206.	2.3	5
9	Australia's National Mental Health Service Planning Framework: Are opinion-based algorithms driving mental health policy?. Australian and New Zealand Journal of Psychiatry, 2020, 54, 1149-1151.	2.3	9
10	Jumping off the bandwagon: Does the Basaglian de-hospitalised model work outside Trieste?. Australian and New Zealand Journal of Psychiatry, 2020, 54, 960-961.	2.3	3
11	Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. CNS Drugs, 2020, 34, 473-507.	5.9	38
12	The challenges facing the public mental health sector: implications of the Victorian Psychiatry workforce project. Australasian Psychiatry, 2019, 27, 618-621.	0.7	5
13	Psychiatric bed numbers in Australia. Lancet Psychiatry, the, 2019, 6, e21.	7.4	3
14	Have we overlooked the significance of multinodal hallucinations in schizophrenia?. Psychiatry Research, 2019, 279, 358-360.	3.3	14
15	Targeting Zero: Implications for public psychiatric services. Australian and New Zealand Journal of Psychiatry, 2017, 51, 560-562.	2.3	4
16	Acceptance and commitment therapy for psychosis: Randomised controlled trial. British Journal of Psychiatry, 2017, 210, 140-148.	2.8	64
17	Understanding the pathophysiology of schizophrenia: Contributions from the Melbourne Psychiatric Brain Bank. Schizophrenia Research, 2016, 177, 108-114.	2.0	10
18	Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. Psychiatry Research, 2015, 230, 982-983.	3.3	11

#	ARTICLE	IF	CITATIONS
19	A randomised controlled trial of acceptance and commitment therapy (ACT) for psychosis: study protocol. <i>BMC Psychiatry</i> , 2014, 14, 198.	2.6	22
20	Pharmacological approaches to the management of schizophrenia: 10 years on. <i>Australasian Psychiatry</i> , 2013, 21, 329-334.	0.7	7
21	A randomised controlled trial of acceptance-based cognitive behavioural therapy for command hallucinations in psychotic disorders. <i>Behaviour Research and Therapy</i> , 2012, 50, 110-121.	3.1	115
22	Who's left? Symptoms of schizophrenia that predict clinical trial dropout. <i>Human Psychopharmacology</i> , 2011, 26, 609-613.	1.5	7
23	Functional connectivity estimation in fMRI data: Influence of preprocessing and time course selection. <i>Human Brain Mapping</i> , 2008, 29, 1040-1052.	3.6	37
24	N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia – A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2008, 64, 361-368.	1.3	489
25	Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2008, 33, 2187-2199.	5.4	321
26	Differential Effects of Acute Serotonin and Dopamine Depletion on Prepulse Inhibition and P50 Suppression Measures of Sensorimotor and Sensory Gating in Humans. <i>Neuropsychopharmacology</i> , 2008, 33, 1653-1666.	5.4	42
27	Acting on Harmful Command Hallucinations in Psychotic Disorders. <i>Journal of Nervous and Mental Disease</i> , 2008, 196, 390-398.	1.0	28
28	The voices acceptance and action scale (VAAS): Pilot data. <i>Journal of Clinical Psychology</i> , 2007, 63, 593-606.	1.9	101
29	Clozapine decreases [3H] CP 55940 binding to the cannabinoid1 receptor in the rat nucleus accumbens. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2005, 371, 428-433.	3.0	41
30	EEG coherence measures during auditory hallucinations in schizophrenia. <i>Psychiatry Research</i> , 2005, 136, 189-200.	3.3	80
31	Diseases of white matter and schizophrenia-like psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2005, 39, 746-756.	2.3	5
32	The endogenous cannabinoid system in schizophrenia. , 2004, , 127-141.		2
33	On the non-significance of internal versus external auditory hallucinations. <i>Schizophrenia Research</i> , 2004, 69, 1-6.	2.0	93
34	Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects. <i>Schizophrenia Research</i> , 2004, 71, 383-392.	2.0	24
35	Partnerships between academic psychiatry and the pharmaceutical industry: the Lilly MAP Initiative. <i>Australasian Psychiatry</i> , 2004, 12, 220-224.	0.7	1
36	Studies on serotonergic markers in the human hippocampus: changes in subjects with bipolar disorder. <i>Journal of Affective Disorders</i> , 2003, 75, 65-69.	4.1	21

#	ARTICLE	IF	CITATIONS
37	Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia. <i>Biological Psychiatry</i> , 2003, 53, 585-592.	1.3	29
38	Command Hallucinations and Violence: Implications for Detention and Treatment. <i>Psychiatry, Psychology and Law</i> , 2003, 10, 97-107.	1.2	44
39	Competence to Give Informed Consent to Research Participation in Persons with Schizophrenia and Related Psychosis. <i>Psychiatry, Psychology and Law</i> , 2003, 10, 85-90.	1.2	2
40	The heterogeneity of central benzodiazepine receptor subtypes in the human hippocampal formation, frontal cortex and cerebellum using [3H]flumazenil and zolpidem. <i>Molecular Brain Research</i> , 2002, 104, 203-209.	2.3	9
41	[3H]Flumazenil binding in the human hippocampal formation, frontal cortex and cerebellum detected by high-resolution phosphorimaging. <i>Brain Research</i> , 2002, 926, 27-32.	2.2	3
42	A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia. <i>Schizophrenia Research</i> , 2001, 52, 37-46.	2.0	135
43	Selective bilateral hippocampal volume loss in chronic schizophrenia. <i>Biological Psychiatry</i> , 2001, 50, 531-539.	1.3	63
44	How Reliable are Reported Plasma Clozapine Levels?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2001, 35, 468-473.	2.3	4
45	A change in the density of [3H]flumazenil, but not [3H]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder. <i>Journal of Affective Disorders</i> , 2001, 66, 147-158.	4.1	44
46	Biological Markers and Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, S108-S112.	2.3	3
47	Neurobiological findings in early phase schizophrenia. <i>Brain Research Reviews</i> , 2000, 31, 157-165.	9.0	52
48	Serotonin _{2A} receptors are reduced in the planum temporale from subjects with schizophrenia. <i>Schizophrenia Research</i> , 2000, 44, 35-45.	2.0	40
49	Steady-state visually evoked potential topography during the continuous performance task in normal controls and schizophrenia. <i>Clinical Neurophysiology</i> , 2000, 111, 850-857.	1.5	47
50	Dopamine Receptors Mediate Estrogen-Induced Stimulation of Hypothalamic Atrial Natriuretic Factor Neurons. <i>Molecular Endocrinology</i> , 1999, 13, 344-352.	3.7	15
51	Hubris and Humility in the Life of the Schizophrenia Researcher. <i>Australian and New Zealand Journal of Psychiatry</i> , 1999, 33, 299-306.	2.3	11
52	Decreased hippocampal (CA3) NMDA receptors in schizophrenia. <i>Synapse</i> , 1999, 32, 67-69.	1.2	33
53	Kallmann syndrome gene (KAL-X) is not mutated in schizophrenia. , 1999, 88, 34-37.		7
54	The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. <i>Life Sciences</i> , 1999, 64, 1761-1771.	4.3	93

#	ARTICLE	IF	CITATIONS
55	Ventriculomegaly and reduced hippocampal volume following intrauterine growth-restriction: implications for the aetiology of schizophrenia. <i>Schizophrenia Research</i> , 1999, 40, 11-21.	2.0	111
56	Hippocampal Volume in First-Episode Psychoses and Chronic Schizophrenia. <i>Archives of General Psychiatry</i> , 1999, 56, 133.	12.3	333
57	Decreased serotonin _{2A} receptors in Brodmann's area 9 from schizophrenic subjects. <i>Molecular and Chemical Neuropathology</i> , 1998, 34, 133-145.	1.0	34
58	Clozapine and olanzapine treatment decreases rat cortical and limbic GABA _A receptors. <i>European Journal of Pharmacology</i> , 1998, 349, R7-R8.	3.5	57
59	The Clinical Use of Plasma Clozapine Levels. <i>Australian and New Zealand Journal of Psychiatry</i> , 1998, 32, 567-574.	2.3	44
60	No Association between the Serotonin Transporter-Linked Promoter Region Polymorphism and Either Schizophrenia or Density of the Serotonin Transporter in Human Hippocampus. <i>Molecular Medicine</i> , 1998, 4, 671-674.	4.4	51
61	Ocular Abnormalities in Chronic Schizophrenia: Clinical Implications. <i>Australian and New Zealand Journal of Psychiatry</i> , 1997, 31, 252-256.	2.3	29
62	The Binding of Both [³ H]Nemonapride and [³ H]Raclopride Is Increased in Schizophrenia. <i>Biological Psychiatry</i> , 1997, 42, 648-654.	1.3	27
63	[³ H]Nemonapride Binding in Human Caudate and Putamen. <i>Brain Research Bulletin</i> , 1997, 44, 167-170.	3.0	5
64	Neither protein kinase C nor adenylate cyclase are altered in the striatum from subjects with schizophrenia. <i>Schizophrenia Research</i> , 1996, 22, 159-164.	2.0	9
65	A clinical trial of the effects of estrogen in acutely psychotic women. <i>Schizophrenia Research</i> , 1996, 20, 247-252.	2.0	166
66	Diagnosis and phenomenology of schizophrenia and related disorders. <i>Current Opinion in Psychiatry</i> , 1996, 9, 63-67.	6.3	1
67	Gonadotropin response to naloxone challenge in female and male psychotic patients: A pilot study. <i>Biological Psychiatry</i> , 1995, 38, 701-703.	1.3	3
68	Neil Conaghy: An Appreciation. <i>Australasian Psychiatry</i> , 1993, 1, 28-31.	0.7	1
69	Symptomatic Response to Antipsychotics Differs between Recent Onset and Recurrent Chronic Schizophrenic Patients. <i>Australian and New Zealand Journal of Psychiatry</i> , 1992, 26, 417-422.	2.3	4
70	Psychotic symptoms resulting from intraventricular infusion of dopamine in Parkinson's disease. <i>Biological Psychiatry</i> , 1992, 31, 1225-1227.	1.3	7
71	Atrial Natriuretic Factor is Released into Hypophysial Portal Blood: Direct Evidence that Atrial Natriuretic Factor may be a Neurohormone Involved in Hypothalamic Pituitary Control. <i>Journal of Neuroendocrinology</i> , 1990, 2, 15-18.	2.6	47
72	Aubrey Lewis Unit, Royal Park Hospital. <i>Psychiatric Bulletin</i> , 1990, 14, 739-740.	0.3	0

#	ARTICLE	IF	CITATIONS
73	Postmortem studies of the brain cannabinoid system in schizophrenia. , 0, , 184-192.		0